Drugs Made In America appoints Roger Bendelac as CEO after Lynn Stockwell resignation

About this update from Drugs Made In America Acquisition Ii Corp.

Drugs Made In America appointed Roger Bendelac as Chief Executive Officer effective February 28, 2026, following the resignation and removal of Lynn Stockwell as CEO, Executive Chair and director.IndividualLynn StockwellRoger BendelacRoleChief Executive Officer; Executive Chair of the Board; Board memberChief Executive OfficerType of ChangeResigned and removedAppointedEffective DateFebruary 28, 2026 (resignation effective upon receipt)February 28, 2026ReasonBoard-directed resignation following Sponsor withdrawals/overpayment and Sponsor's inability to repay overpayment amountAppointment by Board following Stockwell's resignation related to Sponsor conductReplacement InfoReplaced by Roger Bendelac as CEOReplaced Lynn Stockwell as CEOBackground DetailsNot disclosed69; 30+ years in investment banking, capital markets, corporate advisory; consultant with Silverbear Inc. since Sept 2025; director roles at Apex AI Solutions Limited (since Sept 2025), Opencap Global Inc. (since Mar 2018); president/director of SP Associates Corp. since Mar 2016; secretary of RB Consulting Group Ltd. since Apr 2023Board/Committee Role ChangesRemoved as Executive Chair and Board memberNot disclosedOriginal SEC Filing: This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

View stock analysis, news, and events for Drugs Made In America Acquisition Ii Corp.